IdarubicinCytarabineDaunorubicinLeukemia, Myeloid, AcuteAntibiotics, AntineoplasticRemission InductionConsolidation ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsMitoxantroneLeukemia, MyeloidThioguanineEtoposideInduction ChemotherapyArabinonucleosidesAnthracyclinesAntimetabolites, AntineoplasticDoxorubicinVincristinePrecursor Cell Lymphoblastic Leukemia-LymphomaDrug Administration ScheduleTreatment OutcomeNaphthacenesAcute DiseaseMethotrexate6-MercaptopurineAnemia, Refractory, with Excess of BlastsP-GlycoproteinLeukemia, Promyelocytic, AcuteLeukemiaVidarabineDioxolanesDisease-Free SurvivalAntineoplastic AgentsVerapamilDrug Resistance, MultipleRecurrenceDose-Response Relationship, DrugDrug Resistance, NeoplasmAsparaginaseSurvival AnalysisLymphoma, Non-HodgkinDrug AgonismSurvival RateCyclophosphamideAclarubicinDrug EvaluationLeukemia, Myelomonocytic, AcuteMeningeal CarcinomatosisSalvage TherapyTrypanosoma rangeliMyelodysplastic SyndromesInjections, SpinalLeukemic InfiltrationLiposomesInfusions, IntravenousAmsacrineCyclosporinsCytidine MonophosphateDrug ResistanceCarmustineDeoxycytidine KinaseGuanidineTeniposideArabinonucleotidesLeukemia P388Leukemia, Myeloid, Accelerated PhaseTopoisomerase InhibitorsCentral Nervous System NeoplasmsTretinoinHL-60 CellsArabinofuranosylcytosine TriphosphateTransplantation, AutologousCombined Modality TherapyScleromyxedemaTrimethylsilyl CompoundsLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrednisoneBlast CrisisDrug Screening Assays, AntitumorRomeFiltering SurgeryDrug SynergismPrognosisFasciaDexamethasone